Decreased plasma apolipoprotein AIV levels in patients with acute coronary syndrome

Clinical and Investigative Medicine

Volumn 36, Issue 4, 2013, Pages

  Li, Jiabei ^a   Song, Mingbao ^a   Qian, Dehui ^a   Lu, Wei ^a   Wang, Juan ^a   Jiang, Guoyan ^b   Jin, Jun ^a   Wu, Xiaojing ^a   Huang, Lan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV; APOLIPOPROTEIN A4;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIDDLE AGED;

ACUTE CORONARY SYNDROME; AGED; APOLIPOPROTEINS A; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84884528026     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Swaney JB, Braithwaite F, Eder HA. Characterization of the apolipoproteins of rat plasma lipoproteins. Biochemistry 1977;16:271-8.
2. Kalogeris TJ, Fukagawa K, Tsuchiya T, Qin X, Tso P. Intestinal synthesis and lymphatic secretion of apolipoprotein A-IV after cessation of duodenal fat infusion: mediation by bile. Biochim Biophys Acta 1999;1436:451-66.
3. Deng X, Morris J, Dressmen J, Tubb MR, Tso P, Jerome WG, Davidson WS, Thompson TB. The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure 2012;20:767-79.
4. Qin X, Tso P. The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets 2005;6:145-51.
5. Lo CM, Zhang DM, Pearson K, Ma L, Sun W, Sakai RR, Davidson WS, Liu M, Raybould HE, Woods SC, Tso P. Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am J Physiol Regul Integr Comp Physiol 2007;293:R1490-4.
6. Lo CC, Langhans W, Georgievsky M, Arnold M, Caldwell JL, Cheng S, Liu M, Woods SC, Tso P. Apolipoprotein AIV Requires Cholecystokinin and Vagal Nerves to Suppress Food Intake. Endocrinology 2012;153:5857-65.
7. Kohan AB, Wang F, Li X, Bradshaw S, Yang Q, Caldwell JL, Bullock TM, Tso P. Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function. Am J Physiol Gastrointest Liver Physiol 2012;302:G628-36.
8. von Eckardstein A, Huang Y, Wu S, Sarmadi AS, Schwarz S, Steinmetz A, Assmann G. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cellderived cholesterol in plasma. Arterioscler Thromb Vasc Biol 1995;15:1755-63.
9. Weinberg RB, Anderson RA, Cook VR, Emmanuel F, Denèfle P, Tall AR, Steinmetz A. Interfacial exclusion pressure determines the ability of apolipoprotein A-IV truncation mutants to activate cholesterol ester transfer protein. J Biol Chem 2002;277:21549-53.
10. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990;265:4266-72.
11. Recalde D, Ostos MA, Badell E, Garcia-Otin AL, Pidoux J, Castro G, Zakin MM, Scott-Algara D. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004;24:756-61.
12. Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, Kalogeris TJ. Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 2004;114:260-9.
13. Ostos MA, Conconi M, Vergnes L, Baroukh N, Ribalta J, Girona J, Caillaud JM, Ochoa A, Zakin MM. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:1023-8.
14. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998;274:H1836-40.
15. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denèfle P. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996;273:966-8.
16. Cohen RD, Castellani LW, Qiao JH, Van Lenten BJ, Lusis AJ, Reue K. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997;99:1906-16.
17. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, Dieplinger H. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000;36:751-7.
18. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A, Kraft HG, Weidinger F, Pachinger O, Dieplinger H, Kronenberg F. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003;44:1523-9.
19. Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, Humphries SE, Talmud PJ. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 2003;92:969-75.
20. Abbate R, Cioni G, Ricci I, Miranda M, Gori AM. Thrombosis and acute coronary syndrome. Thromb Res 2012;129:235-40.
21. Kumar A, Kar S, Fay WP. Thrombosis, physical activity, and acute coronary syndromes. J Appl Physiol 2011;111:599-605.
22. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2012;60:932-42.
23. Hovland A, Lappegård KT, Mollnes TE. LDL apheresis and inflammation--implications for atherosclerosis. Scand J Immunol 2012;76:229-36.
24. Tinkel J, Hassanain H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012;20:77-83.
25. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.
26. Reriani MK, Flammer AJ, Jama A, Lerman LO, Lerman A. Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome. Circ J 2012;76:778-83.
27. Ramasamy I. Biochemical markers in acute coronary syndrome. Clin Chim Acta 2011;412:1279-96.
28. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation 2012;125:1147-56.
29. Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI. Apolipoprotein A-IV promotes the biogenesis of apoA-IV containing HDL particles with theparticipation of ABCA1 and LCAT. J Lipid Res 2013;54:107-15.
30. Spaulding HL, Saijo F, Turnage RH, Aw TY, Kalogeris TJ. Apolipoprotein A-IV attenuates oxidant-induced apoptosis in mitotic competent, undifferentiated cells by modulating intracellular glutathione redox balance. Am J Physiol Cell Physiol 2006;290:C95-103.
31. Kollerits B, Krane V, Drechsler C, Lamina C, März W, Ritz E, Wanner C, Kronenberg F; The German Diabetes and Dialysis Study Investigators. Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus - a post hoc analysis of the 4D Study. J Intern Med 2012;272:592-600.
32. Omori M, Watanabe M, Matsumoto K, Honda H, Hattori H, Akizawa T. Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients. Ther Apher Dial 2010;14:341-8.
33. Park JY, Park JH, Jang W, Hwang IK, Kim IJ, Kim HJ, Cho KH, Lee ST. Apolipoprotein A-IV is a novel substrate for matrix metalloproteinases. J Biochem 2012;151:291-8.
34. Shantsila E, Lip GY. Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol 2009;29:1433-8.
35. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008;11:632-9.
36. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.